Tapentadol and Metabolite, Urine, Quantitative

2003128
copy
 

Copy Utility


emailprint
Example Reports
Negative
Positive
Ordering Recommendation

Preferred test to follow-up presumptive results. For general screening, Tapentadol Urine Screen with Reflex to Quantitation (2012294) is preferred.

Mnemonic
TAPENTA UR
Methodology

Quantitative Liquid Chromatography-Tandem Mass Spectrometry

Performed

Sun, Wed, Fri

Reported

1-6 days

New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
Collect

Random urine.

Specimen Preparation

Transfer 2 mL urine with no additives or preservatives to an ARUP Standard Transport Tube. (Min: 1 mL)

Storage/Transport Temperature

Room temperature.

Unacceptable Conditions

Specimens exposed to repeated freeze/thaw cycles.

Remarks
Stability

Ambient: 1 week; Refrigerated: 1 month; Frozen: 3 years.

Reference Interval

Effective August 17, 2015

Drugs Covered Cutoff Concentrations
Tapentadol 50 ng/mL
Tapentadol glucuronide 100 ng/mL
Tapentadol-O-sulfate (qualitative only) 100 ng/mL
N-desmethyltapentadol (qualitative only) 100 ng/mL

Interpretive Data

Methodology: Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Positive Cutoff:
           Tapentadol: 50 ng/mL
           Tapentadol glucuronide: 100 ng/mL
           Tapentadol-O-sulfate: 100 ng/mL
           N-desmethyltapentadol: 100 ng/mL
                                                   
For medical purposes only; not valid for forensic use.

The presence of metabolite(s) without parent drug is not uncommon and may indicate use over the prior week.

The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Note
Hotline History

View Hotline History

 

Hotline History

Date of Change
Test Name Change
Methodology
Performance/Reported Schedule
Specimen Requirements
Reference Interval
Interpretive Data
Note
CPT Code
Component Change
Other Interface Change
New Test
Inactive
02/19/2019
X
N/A
CPT Codes

80372 (Alt code: G0480)

Are you an ARUP Client? Click here for your pricing.
Components
Component Test Code* Component Chart Name LOINC
2003129 Tapentadol, Urn, Quant 65807-0
2003130 N-desmethyltapentadol, Urn, Qual
2005875 Tapentadol glucuronide, Urn, Quant
2005879 Tapentadol-O-sulfate, Urn, Qual
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Nucynta
  • Tapentadol, Quantitative, Urine
  • urine tapentadol concentration
Tapentadol and Metabolite, Urine, Quantitative